The Daily Pennsylvanian2d
Here’s how Penn researchers are using mRNA technology to treat cancer, celiac disease
Penn researchers are developing new treatments using mRNA technology to combat a range of diseases, namely celiac disease ...
Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
Life-Saving Cancer Vaccine for Women Expected Within 6 Months
Union Minister Prataprao Jadhav said vaccine to fight cancers affecting women will be available in five to six months. Read ...
Moderna, Inc.: Working Hard But Competition Is Working Harder
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Cancer vaccine for women to be available in six months; check details
The vaccine will be administered to girls between the ages of nine and 16 as part of the government’s initiative to address the rising number of cancer cases in the country.
Montana seeks to ban mRNA shots as vaccine hesitancy soars
Health Secretary Robert F. Kennedy Jr. is a noted vaccine skeptic, and President Donald Trump has expressed concerns about ...
CureVac's SWOT analysis: mRNA pioneer's stock faces pivotal year in vaccine race
CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company specializing in mRNA-based therapies and vaccines with a market ...
Zacks Investment Research on MSN6d
Moderna Q4 Earnings and Revenues Beat, COVID Vaccine Sales Decline
Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...